Franklin Resources’s Franklin Genomic Advancements ETF HELX Stock Holding History

Franklin Resources’s Portfolio HELX Stock Details HELX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$107K	Hold	2,675	–	–	﹤0.01%	2966
2026 Q1	$88.4K	Buy	+2,675	New	+$93.3K	﹤0.01%	2948
2020 Q4	–	Sell	-10,000	Closed	-$351K	–	1929
2020 Q3	$351K	Sell	10,000 -55,000	-85%	-$1.87M	﹤0.01%	1550
2020 Q2	$2.23M	Sell	65,000 -10,000	-13%	-$277K	﹤0.01%	1131
2020 Q1	$1.68M	Buy	+75,000	New	+$1.69M	﹤0.01%	1125

Other funds holding HELX

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return

Harbour Investments Madison, Wisconsin $7.43B AUM 24.49% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Franklin Resources's HELX Position: Q2 2026 in Review

Franklin Resources held its Franklin Genomic Advancements ETF (HELX) position steady in Q2 2026 at 2,675 shares worth $107K. The position accounts for ﹤0.01% of the portfolio, ranked #2966.

Franklin Resources first reported a position in HELX in Q1 2020 and has held it in 5 quarters since. The position peaked at $2.23M in Q2 2020. 6 funds tracked by Wall St. Rank hold HELX as of Q2 2026.

Franklin Resources held 2,675 shares of Franklin Genomic Advancements ETF worth $107K as of Q2 2026.
Franklin Resources left its Franklin Genomic Advancements ETF share count unchanged in Q2 2026.
Franklin Genomic Advancements ETF made up ﹤0.01% of Franklin Resources's portfolio in Q2 2026, its #2966 holding.
Franklin Resources first reported a position in Franklin Genomic Advancements ETF in Q1 2020 and has held it in 5 quarters since.
Franklin Resources's Franklin Genomic Advancements ETF position peaked at $2.23M in Q2 2020.
6 funds tracked by Wall St. Rank held Franklin Genomic Advancements ETF as of Q2 2026.

Based on Franklin Resources's 13F filing for Q2 2026, filed 13 Aug 2026.